Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prospective Longitudinal Study on Immunogenicity, Induction of Cellular Immune Responses and Safety of Vaccination Against HPV With the 9-valent Vaccine in HIV-positive Women (The Papillon Study)

Next Previous
X
Search
Trial Profile

Prospective Longitudinal Study on Immunogenicity, Induction of Cellular Immune Responses and Safety of Vaccination Against HPV With the 9-valent Vaccine in HIV-positive Women (The Papillon Study)

Status: Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 09 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs V 503 (Primary)
  • Indications Human papillomavirus infections
  • Focus Pharmacodynamics
  • Acronyms Papillon; the Papillon Study

    • Most Recent Events

    • 06 Feb 2024 Planned End Date changed from 2 May 2023 to 2 May 2026.
    • 19 Jul 2022 Planned End Date changed from 8 Jan 2023 to 2 May 2023.
    • 19 Jul 2022 Planned primary completion date changed from 1 Nov 2021 to 2 May 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top